PreveCeutical Engages Phoenix Corporate Finance for Strategic Advisory Services

PreveCeutical Medical Inc., a health sciences company developing innovative preventive and curative therapies, has announced that it has engaged Toronto-based Phoenix Corporate Finance Inc. as its advisory firm to provide strategic and corporate advisory services relating to potential future transactions.

Unlocking New Possibilities in Preventive Health Sciences

Transitioning from R&D to Clinical Phase

As PreveCeutical transitions from research and development into the clinical phase, the company recognizes the need for strategic partnerships and an evolution in its approach to its four research programs. The company plans to dedicate additional resources and human talent to each of the different programs, tailoring the efforts to the specific medical fields of the respective therapies.PreveCeutical's Chairman and CEO, Mr. Stephen Van Deventer, commented, "As PreveCeutical transitions from R&D into the clinical phase, we believe moving forward will require strategic partnerships and an evolution as to how we approach each of our four research programs. Over the coming months we will dedicate additional resources and human talent to each of the different programs that are specific to the medical field of each therapy."

Diversifying the Research Portfolio

PreveCeutical's research and development portfolio encompasses a diverse range of innovative programs, including:- Dual gene therapy for curative and prevention therapies for diabetes and obesity- The Sol-gel Program- Nature Identical peptides for the treatment of various ailments- Nonaddictive analgesic peptides as a replacement for highly addictive painkillers like morphine, fentanyl, and oxycodone- A therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury)By diversifying its research efforts, PreveCeutical aims to position itself as a leader in preventive health sciences, offering a range of innovative solutions to address various medical conditions and needs.

Engaging Phoenix Corporate Finance for Strategic Guidance

In line with its strategic transition, PreveCeutical has engaged Phoenix Corporate Finance Inc. as its advisory firm. Under the engagement, Phoenix will provide corporate advisory services to the company with respect to potential strategic transactions, including the potential acquisition or disposition of assets.As consideration for the services, PreveCeutical has agreed to pay Phoenix an aggregate of ,000 plus applicable taxes. This investment in strategic advisory services reflects PreveCeutical's commitment to exploring and executing on opportunities that can further strengthen its position in the preventive health sciences landscape.

Positioning for the Future

PreveCeutical's engagement of Phoenix Corporate Finance is a significant step in the company's evolution. By tapping into the expertise and guidance of a reputable advisory firm, PreveCeutical aims to navigate the complexities of the healthcare industry and identify strategic partnerships or transactions that can propel its research and development efforts forward.As the company transitions from the R&D phase to the clinical phase, this advisory engagement underscores PreveCeutical's dedication to positioning itself for long-term success and its unwavering commitment to developing innovative solutions that can positively impact the lives of individuals seeking preventive and curative therapies.